Research programme: antibody-drug conjugates - Mersana Therapeutics/Merck KGaA
Latest Information Update: 10 Mar 2017
At a glance
- Originator EMD Serono; Merck KGaA; Mersana Therapeutics
- Developer EMD Serono; Mersana Therapeutics
- Class Antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Cancer